Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Argus Health
Dow
Colorcon
Chubb
Baxter
US Department of Justice
Julphar
McKinsey

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020845

« Back to Dashboard

NDA 020845 describes INOMAX, which is a drug marketed by Mallinckrodt Hosp and is included in one NDA. It is available from one supplier. There are fifteen patents protecting this drug and one Paragraph IV challenge. Additional details are available on the INOMAX profile page.

The generic ingredient in INOMAX is nitric oxide. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nitric oxide profile page.
Summary for 020845
Tradename:INOMAX
Applicant:Mallinckrodt Hosp
Ingredient:nitric oxide
Patents:15
Formulation / Manufacturing:see details
Pharmacology for NDA: 020845
Physiological EffectVasodilation
Suppliers and Packaging for NDA: 020845
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
INOMAX nitric oxide GAS;INHALATION 020845 NDA INO Therapeutics 64693-002 N 64693-002-01
INOMAX nitric oxide GAS;INHALATION 020845 NDA INO Therapeutics 64693-002 N 64693-002-02

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:GAS;INHALATIONStrength100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Dec 23, 1999TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Dec 30, 2029Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Try a Free TrialPatent Expiration:Jul 6, 2031Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Try a Free TrialPatent Expiration:Dec 30, 2029Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 020845

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mallinckrodt Hosp INOMAX nitric oxide GAS;INHALATION 020845-002 Dec 23, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Mallinckrodt Hosp INOMAX nitric oxide GAS;INHALATION 020845-003 Dec 23, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Mallinckrodt Hosp INOMAX nitric oxide GAS;INHALATION 020845-003 Dec 23, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Mallinckrodt Hosp INOMAX nitric oxide GAS;INHALATION 020845-003 Dec 23, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Accenture
Baxter
Julphar
AstraZeneca
Cantor Fitzgerald
Covington
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.